Cochrane · systematic review · CD009019
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children
Kew, KM, Karner, C, Mindus, SM, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
2
Included studies
NR
No studies 2 · 40%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 2 · 40%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
SiT for maintenance/relief compared with higher‐dose ICS/LABA + SABA for chronic asthma in adults and children
Population: Studies recruited adults and adolescents aged 12 and older with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA | no estimate extracted | NR | No studies |
People with exacerbations requiring hospitalisation SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA | no estimate extracted | NR | No studies |
Patients with exacerbations requiring oral steroids SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA | OR 0.75 [0.65, 0.87] | 9096 participants | High |
Patients with serious adverse events SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA | OR 0.92 [0.74, 1.13] | 9130 participants | Moderate Downgraded: risk of bias, imprecision |
Patients with severe exacerbations (requiring hospitalisation or ER visit) SiT for maintenance/relief vs higher‐dose ICS/LABA + SABA | OR 0.72 [0.57, 0.9] | 7768 participants | High |